Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Trial details
- Registry ID
- NCT06162221
- Phase
- Phase 1, Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCNCT06162221 | RVMD | Phase 1, Phase 2 | Recruiting | 2027-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |